Human Genome Epidemiology Literature Finder
Records 1 - 4 (of 4 Records) |
Query Trace: Stomatitis and MTOR[original query] |
---|
Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. Cancer chemotherapy and pharmacology 2016 May . de Wit D, Schneider T C, Moes D J A R, Roozen C F M, den Hartigh J, Gelderblom H, Guchelaar H J, van der Hoeven J J, Links T P, Kapiteijn E, van Erp N |
Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial. The Journal of clinical endocrinology and metabolism 2016 Nov jc20162525. Schneider T C, de Wit D, Links T P, van Erp N P, van der Hoeven J J M, Gelderblom H, Roozen C F M, Bos M, Corver W E, van Wezel T, Smit J W A, Morreau H, Guchelaar H J, Kapiteijn |
LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Breast cancer research and treatment 2018 Jun . Van Swearingen Amanda E D, Siegel Marni B, Deal Allison M, Sambade Maria J, Hoyle Alan, Hayes D Neil, Jo Heejoon, Little Paul, Dees Elizabeth Claire, Muss Hyman, Jolly Trevor, Zagar Timothy M, Patel Nirali, Miller C Ryan, Parker Joel S, Smith J Keith, Fisher Julie, Shah Nikita, Nabell Lisle, Nanda Rita, Dillon Patrick, Abramson Vandana, Carey Lisa A, Anders Carey |
Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer. Journal of Cancer 2018 9 (7): 1145-1151. Park In Hae, Kong Sun-Young, Kwon Youngmee, Kim Min Kyeong, Sim Sung Hoon, Joo Jungnam, Lee Keun Se |
- Page last reviewed:Feb 1, 2024
- Content source: